Innohep

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injectable solution for subcutaneous administration. It is employed to prevent deep‑vein thrombosis in surgical patients, treat acute DVT and pulmonary embolism, and maintain circuit patency during hemodialysis. The medication is supplied in multi‑dose vials that are stored under refrigerated conditions to preserve stability.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is a low molecular weight heparin used in the prevention and treatment of venous thromboembolism. - Prevention of deep vein thrombosis (surgical patients): Reduces incidence of postoperative clot formation. - Treatment of acute deep vein thrombosis: Facilitates clot resolution and prevents extension. - Treatment of pulmonary embolism: Provides anticoagulation to limit further embolic events. - Prevention of clot formation in hemodialysis circuits: Maintains circuit patency during dialysis sessions.

Innohep may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain or erythema. - Minor bruising or hematoma at the injection site. - Mild bleeding such as epistaxis or gum bleeding. - Transient elevation of liver enzymes. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT). - Spinal or epidural hematoma after neuraxial procedures. - Severe allergic reactions or anaphylaxis. - Thrombosis paradoxically associated with HIT.

Before initiating Innohep, clinicians should evaluate individual risk factors and follow recommended safety measures. - Renal impairment: Adjust dosing or monitor anti‑Xa activity in patients with reduced kidney function. - Bleeding risk: Assess for active bleeding, recent surgery, or coagulopathy before use. - Concomitant anticoagulants: Avoid combining with other systemic anticoagulants unless specifically indicated. - Pregnancy: Use only when the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vials.

Innohep can interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants). - Systemic thrombolytic agents (e.g., alteplase). - Dual antiplatelet therapy that includes potent agents (e.g., clopidogrel) when combined with full‑dose tinzaparin.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic drugs. - ACE inhibitors, which can potentiate hypotensive effects in the setting of bleeding.